2. Antithrombotic Therapy for Coronary Stenting

2005 ◽  
pp. 499-520
Keyword(s):  
Antithrombotic Therapy ◽  
Coronary Stenting

Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting

2017 ◽  
Vol 6 (1) ◽  
pp. 91-117 ◽  
Author(s):  
Mikhail S. Dzeshka ◽  
Richard A. Brown ◽  
Davide Capodanno ◽  
Gregory Y.H. Lip
Keyword(s):  
Atrial Fibrillation ◽  
Antithrombotic Therapy ◽  
Coronary Stenting

Antithrombotic Therapy After Coronary Stenting in Patients With Nonvalvular Atrial Fibrillation

2013 ◽  
Vol 29 (2) ◽  
pp. 213-218 ◽  
Author(s):  
Kay W. Ho ◽  
Joan Ivanov ◽  
Xavier Freixa ◽  
Christopher B. Overgaard ◽  
Mark D. Osten ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Antithrombotic Therapy ◽  
Coronary Stenting ◽  
Nonvalvular Atrial Fibrillation

scholarly journals Antithrombotic management of patients with acute coronary syndrome and atrial fibrillation undergoing coronary stenting: a prospective, observational, nationwide study

BMJ Open ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. e041044
Author(s):  
Leonardo De Luca ◽  
Andrea Rubboli ◽  
Leonardo Bolognese ◽  
Lucio Gonzini ◽  
Stefano Urbinati ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Acute Coronary Syndrome ◽  
Antithrombotic Therapy ◽  
Multivariable Analysis ◽  
Bleeding Event ◽  
Coronary Stenting ◽  
Secondary Outcome ◽  
Pharmacological Management ◽  
Nationwide Study ◽  
Coronary Syndrome

ObjectiveThe aim of the study was to assess current management of patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) undergoing coronary stenting.DesignNon-interventional, prospective, nationwide study.Setting76 private or public cardiology centres in Italy.ParticipantsPatients with ACS with concomitant AF undergoing percutaneous coronary intervention (PCI).Primary and secondary outcome measuresTo obtain accurate and up-to-date information on pharmacological management of patients with AF admitted for an ACS and undergoing PCI with stent implantation.ResultsOver a 12-month period, 598 consecutive patients were enrolled: 48.8% with AF at hospital admission and 51.2% developing AF during hospitalisation. At discharge, a triple antithrombotic therapy (TAT) was prescribed in 64.8%, dual antiplatelet therapy (DAPT) in 25.7% and dual antithrombotic therapy (DAT) in 8.8% of patients. Among patients with AF at admission, TAT and DAT were more frequently prescribed compared with patients with new-onset AF (76.3% vs 53.8% and 12.5% vs 5.3%, respectively; both p<0.0001), while a DAPT was less often used (11.2% vs 39.5%; p<0.0001). At multivariable analysis, a major bleeding event (OR: 5.40; 95% CI: 2.42 to 12.05; p<0.0001) and malignancy (OR: 5.11; 95% CI: 1.77 to 14.78; p=0.003) resulted the most important independent predictors of DAT prescription.ConclusionsIn this contemporary registry of patients with ACS with AF treated with coronary stents, TAT still resulted as the antithrombotic strategy of choice, DAT was reserved for high bleeding risk and DAPT was mainly prescribed in those developing AF during hospitalisation.Trial registration numberNCT03656523.

Short-duration triple antithrombotic therapy for atrial fibrillation patients who require coronary stenting: results of the SAFE-A study

2020 ◽  
Vol 16 (2) ◽  
pp. e164-e172 ◽  
Author(s):  
Tomoya Hoshi ◽  
Akira Sato ◽  
Daigo Hiraya ◽  
Hiroaki Watabe ◽  
Noriyuki Takeyasu ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Short Duration ◽  
Antithrombotic Therapy ◽  
Coronary Stenting ◽  
Triple Antithrombotic Therapy
Sign in / Sign up

Export Citation Format

Share Document